InvestorsHub Logo
Followers 829
Posts 119609
Boards Moderated 14
Alias Born 09/05/2002

Re: jmkobers post# 542

Sunday, 01/13/2019 8:15:33 PM

Sunday, January 13, 2019 8:15:33 PM

Post# of 7354
Setting the optimal price is a guessing game, but a significantly steeper discount than Dysport and Xeomin could well be counterproductive for EOLS and its physician partners.

The US Enoxaparin market, where there are substitutable generics and large hospital-affiliated buyers, is not a good roadmap for the US botulinum-toxin market, IMO.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent RVNC News